Project Grant R01AR082041

Award Date 6/1/24
Completion Date 5/31/29
Dollars Obligated $534K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award, valued at $366,975.00 and awarded by the National Institute of Neurological Disorders and Stroke (NINDS), supports research to validate a translational animal model of chronic discogenic low back pain. The project, titled "Validation of a Translational Model of Chronic Discogenic Low Back Pain," aims to reproduce and validate a recently published rat model of disc degeneration-induced chronic low back pain. The research is being conducted by experts at...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery and validation of novel non-addictive therapies for...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of California, San Diego (UCSD) a $2,884,007 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate mechanisms of intra- and inter-individual pain variability in patients with comorbid chronic low back pain (CLBP) and major depressive disorder (MDD). The research will generate individualized prediction models of momentary pain intensity using ecological momentary...
This $605,253 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the mechanical crosstalk between the intervertebral disc and facet joints during spinal degeneration and repair. The research aims to characterize the progression of facet osteoarthritis in an animal model following induced intervertebral disc degeneration, as well as...
The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,643,228 Cooperative Agreement grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Worcester Polytechnic Institute (WPI) to develop an Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment (IMPACT). The key objectives of this 2-year IMPACT project are to: 1) Initiate a clinical trial of Mindfulness-Based Stress Reduction (MBSR) for chronic low back pain...
This $14.2 million project grant from the National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, will fund research from September 2022 to August 2025 under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The Massachusetts General Hospital will investigate the mechanisms by which spinal cord stimulation reduces pain, with the goal of improving device design and patient selection. Researchers will apply specialized nerve...
This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a 16-week randomized controlled trial to test the efficacy and biochemical mechanisms of a dietary intervention for adults with chronic axial low back pain. The $376,310 award will fund planning activities, including updating the dietary intervention, preparing...
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...
This $2,370,000 Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced human pluripotent stem cell (HPSC) tools for studying region-specific pain circuits. The key objectives are: 1) Developing scalable methods to generate region-specific sensory neurons and glial subtypes; 2) Creating and characterizing region-specific somatosensory organoids that mimic the in vivo...
The National Institutes of Health National Institute of Neurological Disorders and Stroke awarded an $11.2 million project grant to the University of Pittsburgh to define the mechanisms of pain relief associated with dorsal root ganglion and spinal cord stimulation. This three-year grant will support research under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to advance understanding of neuromodulatory devices for chronic pain treatment. The University will conduct preclinical...

STUDYING THE MECHANISM OF DISCOGENIC LOW BACK PAIN INDUCTION. - PROJECT SUMMARY THE GOAL OF THIS STUDY IS TO ESTABLISH A HUMAN MODEL FOR LOW BACK PAIN (LBP) CAUSED BY INTERVERTEBRAL DISC (IVD) DEGENERATION, AND TO ANSWER THE QUESTION, WHAT CAUSES A DEGENERATIVE DISC TO BECOME PAINFUL? LBP IS A LEADING CAUSE OF DISABILITY AND MORBIDITY IN THE ADULT POPULATION, AFFECTING APPROXIMATELY 80% OF ADULTS. UP TO 40% OF ALL LBP IS ATTRIBUTED TO IVD DEGENERATION, WHICH IS CATEGORIZED AS DISCOGENIC PAIN. RADIOGRAPHICALLY AGED IVDS DO NOT ALWAYS CORRELATE WITH PATHOLOGICALLY PAINFUL DISCS. CURRENT TREATMENTS FOCUS ON PAIN MANAGEMENT AND THE RESTORATION OF DISC HEIGHT, BUT THE UNDERLINING CAUSE FOR DISCOGENIC PAIN REMAINS UNTREATED. IN OUR PREVIOUSLY PUBLISHED AND PRELIMINARY STUDIES WE HAVE ESTABLISHED AN IN VITRO SYSTEM TO SIMULATE IVD DEGENERATION, A NOCICEPTION SENSING WITH SENSORY NEURON DIFFERENTIATED FROM INDUCED PLURIPOTENT STEM CELLS (IPSC), AN IN VIVO BIOASSAY USING A RAT MODEL AND PERFORMED SINGLE CELL TRANSCRIPTOMICS OF PAIN INDUCING AND ASYMPTOMATIC IVD TISSUES AND DEVELOPED A HYPOTHESIS FOR THE PAIN INDUCTION MECHANISM. IN THIS PROPOSAL WE WILL COMBINE THESE SYSTEMS IN NOCICEPTION-CHIP TO UNVEIL THE MOLECULAR AND CELLULAR MECHANISM OF DISCOGENIC PAIN INDUCTION IN VITRO AND IN VIVO. IN AIM 1 WE WILL IDENTIFY THE CELLULAR SUB-POPULATION(S) THAT TRANSFORM ASYMPTOMATIC IVDS TO DISCOGENIC PAIN INDUCING ONES, TEST THE HYPOTHESIS THAT THIS PROCESS IS MEDIATED BY PRO-INFLAMMATORY AGENTS AND INVESTIGATE ITS REVERSIBILITY. THE SINGLE CELL DATA WILL BE UTILIZED TO IDENTIFY SPECIFIC SURFACE CELL MARKERS OF THE SUB- POPULATIONS WITH WHICH WE WILL SORT THE CELLS OUT. WE WILL SIMULATE DISC DEGENERATION MODEL IN VITRO AND TO TEST THE FUNCTIONALITY OF THESE CELLS, IDENTIFY THE CRITICAL FACTORS THAT LEAD TO DEVELOPMENT OF DISCOGENIC PAIN AND TEST THE RESPONSE OF NOCICEPTORS DIFFERENTIATED FROM INDUCED PLURIPOTENT STEM CELLS AS A READOUT OF PAIN SENSING. THE FUNCTIONALITY OF THESE CELLS TO INDUCE LBP BEHAVIOUR WILL BE VALIDATED IN A RAT MODEL. WE WILL TEST THE HYPOTHESIS THAT THIS PROCESS IS MEDIATED BY SPECIFIC INFLAMMATORY FACTORS OR THE LACK OF ANTI-INFLAMMATORY FACTORS LIKE MIR-155 BY CO-INJECTING THEM TO A HEALTHY OR MILDLY DEGENERATED IVDS. IN AIM 2 WE WILL IDENTIFY CELLULAR SUB-POPULATION(S) ENRICHED IN DEGENERATED ASYMPTOMATIC IVDS AND TEST THE HYPOTHESIS THAT THESE CELLS PREVENT THE TRANSFORMATION OF ASYMPTOMATIC TO PAINFUL IVDS. WE WILL LEVERAGE THE SAME DATABASE OF SINGLE CELL TRANSCRIPTOMICS USED IN AIM 1 AND WILL LOOK AT THE NON-PAINFUL DISC PREVALENT CELSL AS POTENTIALLY THERAPIUTICS CELLS. THESE CELLS WILL BE ISOLATED, CHARACTERIZED AND CO-INJECTED WITH PAIN INDUCING CELLS OR TO A DEGENERATED IVDS IN A RAT MODEL THAT ALLOWS MEASUREMENT FOR STRACTURAL AND BEHAVIORAL LBP OUTCOMES. OVERALL, BOTH AIMS ARE NOT INTERDEPENDANT AND WILL CONTAIN HYPOTHESIS-DRIVEN, HYPTHESIS GENERATING AND THERAPITUC COMPONENTS. THIS STUDY IS SIGNIFICANT BECAUSE IT WILL FILL SUBSTANTIAL GAPS IN OUR UNDERSTANDING OF DISCOGENIC PAIN DEVELOPEMENT: ESTABLISH A CONTROLLED SYSTEM IN VITRO TO IDENTIFY THE MAIN CAUSE(S) BEHIND DISCOGENIC PAIN; IDENTIFY MOLECULAR SIGNATURES AND POINT TOWARDS POTENTIAL THERAPEUTIC TARGETS OR CELLULAR POPULATION CHARACTERISTICS. THIS STUDY IS NOVEL, BECAUSE IT WILL ELUCIDATE THE ROLE OF IVD CELLS, THE FACTORS THAT INDUCE DISCOGENIC PAIN AND IMPACTFUL BECAUSE WE WILL IDENTIFY NOVEL THERAPEUTIC TARGETS THAT WILL ALLOW INTERVENTIONS BESIDE THE USE OF ANALGESICS AND OPIOIDS THAT ARE CURRENTLY PRESCRIBED FOR DISCOGENIC PAIN.

Posted 5/21/24, 12:00 AM